Souhaitez-vous accéder aux communiqués récents ?

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) --  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative...

BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...

One California Pet Will Win a Major Prize Package and Head to Hollywood for the Pet Lovers’ Choice Awards

Austin, TX, USA, April 29, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Birdwatching Tourism Market Size, Trends and Insights By Traveler Type (Hard...

Louvain-la-Neuve, Belgium– March 20, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical...

Louvain‑la‑Neuve, Belgique, le 20 mars 2026 — IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélérateurs de particules et premier fournisseur mondial de solutions de...

BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...

Louvain-la-Neuve, Belgium – 19 February 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, and...

Louvain-la-Neuve, Belgium – 19 février 2026 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d'accélérateurs de particules et acteur de premier plan en médecine...

Crosetto’s 3D-CBS can detect tumors with <100 cancer cells at €200, 2-min safe whole-body test with the potential to save >260 lives/device/year